WallStreetZenWallStreetZen

Sectors & IndustriesHealthcareDiagnostics & Research
Best Diagnostic & Research Stocks to Buy Now (2022)
Top diagnostic & research stocks in 2022 ranked by overall Zen Score. See the best diagnostic & research stocks to buy now, according to analyst forecasts for the diagnostics & research industry.

Industry: Diagnostics & Research
Ticker
Company
Dividends Score
Market Cap
Dividend Yield
Payout Ratio
Last Dividend
Annual Dividend
Dividend Percentile
Dividend Dropped Count (L10Y)
Ex-dividend Date
Div. Payment Date
LNTH
LANTHEUS HOLDINGS INC
$3.82BN/A0.00%N/AN/AN/AN/A
SHC
SOTERA HEALTH CO
$2.38BN/A0.00%N/AN/AN/AN/A
SYNH
SYNEOS HEALTH INC
$3.51BN/A0.00%N/AN/AN/AN/A
QDEL
QUIDELORTHO CORP
$6.09BN/A0.00%N/AN/AN/AN/A
FLGT
FULGENT GENETICS INC
$1.06BN/A0.00%N/AN/AN/AN/A
BWAY
BRAINSWAY LTD
$30.62MN/A0.00%N/AN/AN/AN/A
CODX
CO-DIAGNOSTICS INC
$89.66MN/A0.00%N/AN/AN/AN/A
NEOG
NEOGEN CORP
$1.67BN/A0.00%N/AN/AN/AN/A
TWST
TWIST BIOSCIENCE CORP
$1.46BN/A0.00%N/AN/AN/AN/A
DMTK
DERMTECH INC
$69.49MN/A0.00%N/AN/AN/AN/A
DXCM
DEXCOM INC
$45.13BN/A0.00%N/AN/AN/AN/A
PHG
KONINKLIJKE PHILIPS NV
$12.36B6.79%24.80%$0.9641$0.9685%3
A
AGILENT TECHNOLOGIES INC
$44.81B0.56%18.60%$0.2100$0.847%12022-12-302023-01-25
MEDP
MEDPACE HOLDINGS INC
$6.34BN/A0.00%N/AN/AN/AN/A
QGEN
QIAGEN NV
$11.09BN/A0.00%N/AN/AN/AN/A
SERA
SERA PROGNOSTICS INC
$38.15MN/A0.00%N/AN/AN/AN/A
ICLR
ICON PLC
$16.34BN/A0.00%N/AN/AN/AN/A
TMO
THERMO FISHER SCIENTIFIC INC
$215.92B0.21%6.50%$0.3000$1.161%02022-12-142023-01-16
DGX
QUEST DIAGNOSTICS INC
$16.97B1.75%25.00%$0.6600$2.6032%02023-01-172023-02-01
SENS
SENSEONICS HOLDINGS INC
$497.39MN/A0.00%N/AN/AN/AN/A
DRIO
DARIOHEALTH CORP
$110.66MN/A0.00%N/AN/AN/AN/A
LHDX
LUCIRA HEALTH INC
$13.24MN/A0.00%N/AN/AN/AN/A
CDNA
CAREDX INC
$706.16MN/A0.00%N/AN/AN/AN/A
CSTL
CASTLE BIOSCIENCES INC
$627.43MN/A0.00%N/AN/AN/AN/A
BNGO
BIONANO GENOMICS INC
$641.36MN/A0.00%N/AN/AN/AN/A
LH
LABORATORY CORP OF AMERICA HOLDINGS
$20.75B0.92%7.60%$0.7200$2.1614%02022-12-09
DHR
DANAHER CORP
$193.16B0.36%10.40%$0.2500$0.963%1
GENE
GENETIC TECHNOLOGIES LTD
$20.31MN/A0.00%N/AN/AN/AN/A
IDXX
IDEXX LABORATORIES INC
$34.40BN/A0.00%N/AN/AN/AN/A
MXCT
MAXCYTE INC
$551.05MN/A0.00%N/AN/AN/AN/A
WAT
WATERS CORP
$20.06BN/A0.00%N/AN/AN/AN/A
NRC
NATIONAL RESEARCH CORP
$968.14M2.14%60.40%$0.2400$0.8440%22022-12-292023-01-13
BNR
BURNING ROCK BIOTECH LTD
$250.42MN/A0.00%N/AN/AN/AN/A
CHEK
CHECK-CAP LTD
$21.03MN/A0.00%N/AN/AN/AN/A
PRPO
PRECIPIO INC
$16.93MN/A0.00%N/AN/AN/AN/A
BIOC
BIOCEPT INC
$12.11MN/A0.00%N/AN/AN/AN/A
MOTS
MOTUS GI HOLDINGS INC
$5.59MN/A0.00%N/AN/AN/AN/A
STIM
NEURONETICS INC
$164.15MN/A0.00%N/AN/AN/AN/A
PSNL
PERSONALIS INC
$111.71MN/A0.00%N/AN/AN/AN/A
BVS
BIOVENTUS INC
$171.02MN/A0.00%N/AN/AN/AN/A
ME
23ANDME HOLDING CO
$1.38BN/A0.00%N/AN/AN/AN/A
IQV
IQVIA HOLDINGS INC
$38.98BN/A0.00%N/AN/AN/AN/A
MYGN
MYRIAD GENETICS INC
$1.58BN/A0.00%N/AN/AN/AN/A
AWH
ASPIRA WOMEN's HEALTH INC
$46.04MN/A0.00%N/AN/AN/AN/A
ONVO
ORGANOVO HOLDINGS INC
$13.24MN/A0.00%N/AN/AN/AN/A
HSKA
HESKA CORP
$703.88MN/A0.00%N/AN/AN/AN/A
MTD
METTLER TOLEDO INTERNATIONAL INC
$32.41BN/A0.00%N/AN/AN/AN/A
CNTG
CENTOGENE NV
$19.77MN/A0.00%N/AN/AN/AN/A
CRL
CHARLES RIVER LABORATORIES INTERNATIONAL INC
$10.75BN/A0.00%N/AN/AN/AN/A
RNLX
RENALYTIX PLC
$82.76MN/A0.00%N/AN/AN/AN/A
OPGN
OPGEN INC
$7.25MN/A0.00%N/AN/AN/AN/A
OLK
OLINK HOLDING AB (PUBL)
$2.56BN/A0.00%N/AN/AN/AN/A
VIVO
MERIDIAN BIOSCIENCE INC
$1.39BN/A0.00%$0.1250N/AN/A1
XGN
EXAGEN INC
$39.33MN/A0.00%N/AN/AN/AN/A
ISPC
ISPECIMEN INC
$12.83MN/A0.00%N/AN/AN/AN/A
AXDX
ACCELERATE DIAGNOSTICS INC
$75.32MN/A0.00%N/AN/AN/AN/A
PACB
PACIFIC BIOSCIENCES OF CALIFORNIA INC
$2.06BN/A0.00%N/AN/AN/AN/A
ANIX
ANIXA BIOSCIENCES INC
$153.00MN/A0.00%N/AN/AN/AN/A
PKI
PERKINELMER INC
$17.34B0.20%5.70%$0.0700$0.281%02023-01-192023-02-10
NTRA
NATERA INC
$3.79BN/A0.00%N/AN/AN/AN/A
NEO
NEOGENOMICS INC
$1.46BN/A0.00%N/AN/AN/AN/A
HTGM
HTG MOLECULAR DIAGNOSTICS INC
$3.04MN/A0.00%N/AN/AN/AN/A
MYNZ
MAINZ BIOMED NV
$124.26MN/A0.00%N/AN/AN/AN/A
CEMI
CHEMBIO DIAGNOSTICS INC
$9.87MN/A0.00%N/AN/AN/AN/A
BMRA
BIOMERICA INC
$51.09MN/A0.00%N/AN/AN/AN/A
EXAS
EXACT SCIENCES CORP
$8.21BN/A0.00%N/AN/AN/AN/A
SQL
SEQLL INC
$4.86MN/A0.00%N/AN/AN/AN/A
OPK
OPKO HEALTH INC
$1.07BN/A0.00%N/AN/AN/AN/A
RDNT
RADNET INC
$1.19BN/A0.00%N/AN/AN/AN/A
GH
GUARDANT HEALTH INC
$5.07BN/A0.00%N/AN/AN/AN/A
PMD
PSYCHEMEDICS CORP
$32.01M4.59%-52.80%$0.0700$0.2675%12022-12-16
NDRA
ENDRA LIFE SCIENCES INC
$10.68MN/A0.00%N/AN/AN/AN/A
GTH
GENETRON HOLDINGS LTD
$95.50MN/A0.00%N/AN/AN/AN/A
SLNO
SOLENO THERAPEUTICS INC
$8.08MN/A0.00%N/AN/AN/AN/A
NOTV
INOTIV INC
$134.88MN/AN/AN/AN/AN/AN/A
LAB
STANDARD BIOTOOLS INC
$107.84MN/A0.00%N/AN/AN/AN/A
AKU
AKUMIN INC
$92.35MN/A0.00%N/AN/AN/AN/A
PRE
PRENETICS GLOBAL LTD
$205.31MN/A0.00%N/AN/AN/AN/A
CDIO
CARDIO DIAGNOSTICS HOLDINGS INC
$20.63MN/A0.00%N/AN/AN/AN/A
BIAF
BIOAFFINITY TECHNOLOGIES INC
$25.28MN/AN/AN/AN/AN/AN/A
CELC
CELCUITY INC
$124.45MN/A0.00%N/AN/AN/AN/A
ILMN
ILLUMINA INC
$32.40BN/A0.00%N/AN/AN/AN/A
SRDX
SURMODICS INC
$502.07MN/A0.00%N/AN/AN/AN/A
QTNT
QUOTIENT LTD
$2.40MN/A0.00%N/AN/AN/AN/A
VNRX
VOLITIONRX LTD
$120.22MN/A0.00%N/AN/AN/AN/A
BDSX
BIODESIX INC
$56.41MN/A0.00%N/AN/AN/AN/A
ENZ
ENZO BIOCHEM INC
$86.72MN/A0.00%N/AN/AN/AN/A
TTOO
T2 BIOSYSTEMS INC
$11.13MN/A0.00%N/AN/AN/AN/A
TRIB
TRINITY BIOTECH PLC
$26.34MN/AN/A$0.2200N/AN/A0
MDXH
MDXHEALTH SA
$116.51MN/AN/AN/AN/AN/AN/A
NVTA
INVITAE CORP
$619.38MN/A0.00%N/AN/AN/AN/A
OABI
OMNIAB INC
$423.16MN/AN/AN/AN/AN/AN/A
LMDX
LUMIRADX LTD
$371.39MN/A0.00%N/AN/AN/AN/A
VRAX
VIRAX BIOLABS GROUP LTD
$14.79MN/A0.00%N/AN/AN/AN/A

Diagnostic & Research Stocks FAQ

What are the best diagnostic & research stocks to buy right now in Dec 2022?

According to Zen Score, the 3 best diagnostic & research stocks to buy right now are:

1. Lantheus Holdings (NASDAQ:LNTH)


Lantheus Holdings (NASDAQ:LNTH) is the top diagnostic & research stock with a Zen Score of 59, which is 28 points higher than the diagnostic & research industry average of 31. It passed 19 out of 33 due diligence checks and has strong fundamentals. Lantheus Holdings has seen its stock return 108.34% over the past year, overperforming other diagnostic & research stocks by 133 percentage points.

Lantheus Holdings has an average 1 year price target of $107.25, an upside of 93.31% from Lantheus Holdings's current stock price of $55.48.

Lantheus Holdings stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 4 analysts covering Lantheus Holdings, 50% have issued a Strong Buy rating, 50% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

2. Sotera Health Co (NASDAQ:SHC)


Sotera Health Co (NASDAQ:SHC) is the second best diagnostic & research stock with a Zen Score of 58, which is 27 points higher than the diagnostic & research industry average of 31. It passed 19 out of 33 due diligence checks and has strong fundamentals. Sotera Health Co has seen its stock lose -61.03% over the past year, underperforming other diagnostic & research stocks by -37 percentage points.

Sotera Health Co has an average 1 year price target of $13.56, an upside of 60.62% from Sotera Health Co's current stock price of $8.44.

Sotera Health Co stock has a consensus Hold recommendation according to Wall Street analysts. Of the 10 analysts covering Sotera Health Co, 0% have issued a Strong Buy rating, 20% have issued a Buy, 50% have issued a hold, while 0% have issued a Sell rating, and 30% have issued a Strong Sell.

3. Syneos Health (NASDAQ:SYNH)


Syneos Health (NASDAQ:SYNH) is the third best diagnostic & research stock with a Zen Score of 56, which is 25 points higher than the diagnostic & research industry average of 31. It passed 18 out of 33 due diligence checks and has strong fundamentals. Syneos Health has seen its stock lose -65.5% over the past year, underperforming other diagnostic & research stocks by -41 percentage points.

Syneos Health has an average 1 year price target of $52.29, an upside of 53.15% from Syneos Health's current stock price of $34.14.

Syneos Health stock has a consensus Buy recommendation according to Wall Street analysts. Of the 9 analysts covering Syneos Health, 33.33% have issued a Strong Buy rating, 11.11% have issued a Buy, 55.56% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

What are the diagnostic & research stocks with highest dividends?

Out of 9 diagnostic & research stocks that have issued dividends in the past year, the 3 diagnostic & research stocks with the highest dividend yields are:

1. Koninklijke Philips Nv (NYSE:PHG)


Koninklijke Philips Nv (NYSE:PHG) has an annual dividend yield of 6.79%, which is 5 percentage points higher than the diagnostic & research industry average of 1.95%. Koninklijke Philips Nv's dividend payout is not stable, having dropped more than 10% three times in the last 10 years. Koninklijke Philips Nv's dividend has not shown consistent growth over the last 10 years.

Koninklijke Philips Nv's dividend payout ratio of 24.8% indicates that its high dividend yield is sustainable for the long-term.

2. Psychemedics (NASDAQ:PMD)


Psychemedics (NASDAQ:PMD) has an annual dividend yield of 4.59%, which is 3 percentage points higher than the diagnostic & research industry average of 1.95%. Psychemedics's dividend payout is not stable, having dropped more than 10% one times in the last 10 years. Psychemedics's dividend has not shown consistent growth over the last 10 years.

Psychemedics's dividend payout ratio of -52.8% indicates that its high dividend yield might not be sustainable for the long-term.

3. National Research (NASDAQ:NRC)


National Research (NASDAQ:NRC) has an annual dividend yield of 2.14%, which is the same as the diagnostic & research industry average of 1.95%. National Research's dividend payout is not stable, having dropped more than 10% two times in the last 10 years. National Research's dividend has shown consistent growth over the last 10 years.

National Research's dividend payout ratio of 60.4% indicates that its dividend yield is sustainable for the long-term.

Why are diagnostic & research stocks down?

Diagnostic & research stocks were down -1% in the last day, and up 0.92% over the last week.

We couldn't find a catalyst for why diagnostic & research stocks are down.

What are the most undervalued diagnostic & research stocks?

Based on WallStreetZen's Valuation Score, the 3 most undervalued diagnostic & research stocks right now are:

1. Sotera Health Co (NASDAQ:SHC)


Sotera Health Co (NASDAQ:SHC) is the most undervalued diagnostic & research stock based on WallStreetZen's Valuation Score. Sotera Health Co has a valuation score of 86, which is 53 points higher than the diagnostic & research industry average of 33. It passed 6 out of 7 valuation due diligence checks.

Sotera Health Co's stock has dropped -61.03% in the past year. It has underperformed other stocks in the diagnostic & research industry by -37 percentage points.

2. Quidelortho (NASDAQ:QDEL)


Quidelortho (NASDAQ:QDEL) is the second most undervalued diagnostic & research stock based on WallStreetZen's Valuation Score. Quidelortho has a valuation score of 86, which is 53 points higher than the diagnostic & research industry average of 33. It passed 6 out of 7 valuation due diligence checks.

Quidelortho's stock has dropped -34.01% in the past year. It has underperformed other stocks in the diagnostic & research industry by -10 percentage points.

3. Syneos Health (NASDAQ:SYNH)


Syneos Health (NASDAQ:SYNH) is the third most undervalued diagnostic & research stock based on WallStreetZen's Valuation Score. Syneos Health has a valuation score of 86, which is 53 points higher than the diagnostic & research industry average of 33. It passed 6 out of 7 valuation due diligence checks.

Syneos Health's stock has dropped -65.5% in the past year. It has underperformed other stocks in the diagnostic & research industry by -41 percentage points.

Are diagnostic & research stocks a good buy now?

45.88% of diagnostic & research stocks rated by analysts are a strong buy right now. On average, analysts expect diagnostic & research stocks to rise by 22.47% over the next year.

What is the average p/e ratio of the diagnostics & research industry?

The average P/E ratio of the diagnostics & research industry is 35.8x.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.